In conclusion, potential germline mutations affecting the CHEK2 gene should be taken into consideration when exploring the genetic mechanisms of drug resistance among breast and, most likely, also prostatic cancer patients. This evidence concerns the gene CHEK2 and Familial prostate cancer.